Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02862275 · ClinicalTrials.gov registry record · Phase 1

Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer

A Phase 1 study of Hematopoietic and Lymphoid Cell Neoplasm and Metastatic Malignant Solid Neoplasm, sponsored by National Cancer Institute (NCI).

Active
Registry status
Phase 1
Development phase
40
Enrollment target
9
Study locations

NCT02862275: Active Phase 1 study of Hematopoietic and Lymphoid Cell Neoplasm and Metastatic Malignant Solid Neoplasm, sponsored by National Cancer Institute (NCI).

NCT02862275 is a Phase 1 study of Hematopoietic and Lymphoid Cell Neoplasm and Metastatic Malignant Solid Neoplasm that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 40 participants, below the 953-participant average among 104 other Hematopoietic and Lymphoid Cell Neoplasm trials with a reported enrollment target (96% lower). The trial reports 9 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02862275, a Phase 1 study of Hematopoietic and Lymphoid Cell Neoplasm and Metastatic Malignant Solid Neoplasm, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
40 participants
Enrollment target
9
Study locations

Study Summary

This pilot phase I trial studies the side effects of atezolizumab in treating patients with cancer following adoptive cell transfer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Primary Outcome

Will be assessed according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 4.0 (CTCAE version 5.0 will be used starting 04/01/2018). Adverse experiences will be graded and recorded throughout the study and during the follow-up period.

Conditions Studied

Hematopoietic and Lymphoid Cell Neoplasm Metastatic Malignant Solid Neoplasm Unresectable Malignant Solid Neoplasm

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • DRUG Atezolizumab
  • PROCEDURE Biopsy Procedure
  • OTHER Laboratory Biomarker Analysis

Study Locations (9)

Georgia

  • Emory University Hospital Midtown - Atlanta
  • Emory University Hospital/Winship Cancer Institute - Atlanta
  • Emory Saint Joseph's Hospital - Atlanta

Florida

  • Moffitt Cancer Center-International Plaza - Tampa
  • Moffitt Cancer Center - Tampa

California

  • UC San Diego Moores Cancer Center - La Jolla

Ohio

  • Ohio State University Comprehensive Cancer Center - Columbus

Texas

  • M D Anderson Cancer Center - Houston

Ontario

  • University Health Network-Princess Margaret Hospital - Toronto

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2017-05-24
Est. Completion 2026-11-21
Phase Phase 1
National Cancer Institute (NCI)

3,257 total trials

What the registry record for NCT02862275 still lists

NCT02862275 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 953-participant average among 104 other Hematopoietic and Lymphoid Cell Neoplasm trials with a reported enrollment target (96% lower).

The record links to 3 conditions, with Hematopoietic and Lymphoid Cell Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT02862275 lists 9 locations in 6 states (Georgia, Florida, California).

Frequently Asked Questions

What is clinical trial NCT02862275 about?

NCT02862275 is a clinical study titled "Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer". This pilot phase I trial studies the side effects of atezolizumab in treating patients with cancer following adoptive cell transfer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells ...

What is the current status of trial NCT02862275?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2017-05-24. Estimated completion is 2026-11-21.

What conditions does trial NCT02862275 study?

This clinical trial studies the following conditions: Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm.

What interventions are being tested in trial NCT02862275?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Atezolizumab (DRUG), Biopsy Procedure (PROCEDURE), Laboratory Biomarker Analysis (OTHER).

Who is sponsoring clinical trial NCT02862275?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02862275 being conducted?

This trial has 9 study locations across California, Florida, Georgia, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hematopoietic and Lymphoid Cell Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02862275's enrollment target sits among peer trials

40 68th of 104 higher than 33 of 104 other Hematopoietic and Lymphoid Cell Neoplasm trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hematopoietic and Lymphoid Cell Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02862275, the US trial registry maintained by the National Library of Medicine. NCT02862275 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.